Showing 8441-8450 of 9662 results for "".
- Cetaphil Launches the Gentle Power Campaignhttps://practicaldermatology.com/news/20140602-cetaphil_launches_the_gentle_power_campaign/2459221/The new Gentle Power Campaign for Cetaphil brands (Galderma) showcases the brand's products and demonstrates how women balance the demands of their day-to-day lives, just as Cetaphil products balance the daily demands on their skin. Stuart Raetzman, chief executive officer of Galderma L
- Two Gene Mutations Linked to Melanoma of the Eyehttps://practicaldermatology.com/news/20140602-two_gene_mutations_linked_to_melanoma_of_the_eye/2459222/Researchers have elucidated mechanisms of two gene mutations associated with uveal melanoma, identified a therapeutic target for treating uveal melanoma in adults, and provided evidence that an existing therapy can be used to slow eye tumor growth. The presence of one of two gene mutation
- Ichthyosis Patient Raising Awareness, Funds with Hikehttps://practicaldermatology.com/news/20140531-ichthyosis_patient_raising_awareness_funds_with_hike/2459223/To raise awareness of ichthysosis and funds for research, Brian Gass of St. Louis is hiking the Pacific Crest Trail – 2,600 miles from Mexico to Canada, crossing the Sierras, over about 110 days. The 21-year-old college student has the rare genetic skin disease, as do three siblings. The experienced
- NeoStrata Launches Exuviance Triple Microdermabrasionhttps://practicaldermatology.com/news/20140530-neostrata_launches_exuviance_triple_microdermabrasion/2459226/NeoStrata Company's new Exuviance Triple Microdermabrasion, described as a three-part approach to skin renewal in one single treatment, will be available nationwide in August. Exuviance Triple Microdermabrasion is formulated with professional grade crystals and Papaya Enzymes along with 1
- mysoscience Launches Novel Pain Treatmenthttps://practicaldermatology.com/news/20140516-mysoscience_launches_novel_pain_treatment/2459238/myoscience, inc., has launched ioveradegrees, a new option to immediately block pain using the body's natural response to cold without the use of drugs or surgery. The ioveradegrees health treatment utilizes myoscience's platform technology—the Focused Cold Therapy(TM) delivery system—to precisely t
- ALPHAEON Appoints Board Of Directorshttps://practicaldermatology.com/news/20140513-alphaeon_appoints_board_of_directors/2459240/ALPHAEON Corporation, a subsidiary of Strathspey Crown Holdings LLC, appointed a team of prominent leaders in healthcare and business to its board of directors. The new board is comprised of experts from the healthcare industry, politics, science, and education. In addition, the
- Potential New Diagnostic Tools and Therapies for Melanoma in the Foreseeable Futurehttps://practicaldermatology.com/news/20140512-potential_new_diagnostic_tools_and_therapies_for_melanoma_in_the_foreseeable_future/2459241/Oregon State University researchers have identified a biochemical process that may cause normal and healthy skin cells to transform into cancerous melanoma cells. These findings could help predict melanoma exposure and could also lead to future treatments. Melanoma, the deadliest form of
- Bayer Acquires Merck's Consumer Care Business in a $14.2 Billion Cash Transactionhttps://practicaldermatology.com/news/20140508-bayer_acquires_mercks_consumer_care_business_in_a_142_billion_cash_transaction/2459244/Bayer is set to purchase the consumer care unit of Merck and Co., Inc. in a transaction valued at $14.2 billion, acquiring popular products in the cold, allergy, sinus & flu, dermatology (including sun care), foot health and gastrointestinal categories. Bayer's acquisition of Merck's OTC products
- Modernizing Medicine's EMA Achieves ONC HIT 2014 Edition EHR Certificationhttps://practicaldermatology.com/news/20140506-modernizing_medicines_ema_achieves_onc_hit_2014_edition_ehr_certification/2459245/Modernizing Medicine's EMA has achieved ONC HIT 2014 Edition Complete EHR certification, meaning that it will be capable of supporting eligible providers and hospitals with meeting the Stage 1 and Stage 2 Meaningful Use measures of the EHR incentive program. EMA version 4.0 and EMA Mobile version 4.
- XOMA Finalizes Gevokizmab Phase III Clinical Program in Pyoderma Gangrenosumhttps://practicaldermatology.com/news/20140428-xoma_finalizes_gevokizmab_phase_3_clinical_program_in_pyoderma__gangrenosum/2459254/Xoma Corporation finalized the plans for gevokizumab Phase III Program in Pyoderma Gangrenosum (PG). The Phase III Study will include two double-blind placebo-controlled clinical studies with 60 patients who have active PG. Paul Rubin, Senior Vice President,